Cost-effectiveness of lenalidomide plus dexamethasone vs bortezomib plus melphalan and prednisone in transplant-ineligible US patients with newly-diagnosed multiple myeloma
Open Access
- 17 November 2015
- journal article
- research article
- Published by Informa Healthcare in Journal of Medical Economics
- Vol. 19 (3) , 243-258
Abstract
(2016). Cost-effectiveness of lenalidomide plus dexamethasone vs bortezomib plus melphalan and prednisone in transplant-ineligible US patients with newly-diagnosed multiple myeloma. Journal of Medical Economics: Vol. 19, No. 3, pp. 243-258.Keywords
This publication has 44 references indexed in Scilit:
- Persistent Overall Survival Benefit and No Increased Risk of Second Malignancies With Bortezomib-Melphalan-Prednisone Versus Melphalan-Prednisone in Patients With Previously Untreated Multiple MyelomaJournal of Clinical Oncology, 2013
- The High Cost of Cancer Drugs and What We Can Do About ItMayo Clinic Proceedings, 2012
- Cost Effectiveness of Personalized Therapy for First-Line Treatment of Stage IV and Recurrent Incurable Adenocarcinoma of the LungJournal of Oncology Practice, 2012
- Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trialHaematologica, 2011
- A randomized trial with melphalan and prednisone versus melphalan and prednisone plus thalidomide in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantLeukemia & Lymphoma, 2011
- Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myelomaEuropean Journal of Haematology, 2009
- Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple MyelomaNew England Journal of Medicine, 2008
- Rates and Probabilities in Economic ModellingPharmacoEconomics, 2007
- Bortezomib or High-Dose Dexamethasone for Relapsed Multiple MyelomaNew England Journal of Medicine, 2005
- Severe chemotherapy-induced diarrhea in patients with colorectal cancer: a cost of illness analysisSupportive Care in Cancer, 2004